CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing new treatments for tuberculosis using beta-lactam antibiotics, which have been overlooked for this disease. By investigating their pharmacokinetics and pharmacodynamics, the project aims to optimize combination therapies to improve treatment outcomes for drug-resistant tuberculosis pa…
Tuberculosis (TB) is the most deadly infectious disease worldwide. TB therapy takes 6 months with unpleasant side effects that leads to poor adherence and the development of drug resistance.
Patients infected with multi (MDR) or extensively (XDR) drug resistant strains must undergo longer treatments (up to 24 months) associated with even severe side effects and only 30-50% positive treatment outcomes.
New treatments are urgently needed.Beta-lactams (BLMs) are the safest antibiotics in the market…
FUNDACION AGENCIA ARAGONESA PARA LA INVESTIGACION Y EL DESARROLLO
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
